from Goldman Sachs issued a price target of $20.00 for AEVA on 2026-08-24 00:20:28.The adjusted price target was set to $20.00.At the time of the announcement, AEVA was trading at $18.29.The overall price target consensus is at $28.75 with high price of $42.00, low price of $20.00, and median price is at $26.50.AEVA currently trades...
Goldman Sachs analyst issues NEUTRAL recommendation for AEVA on August 24, 2026 12:20AM ET. AEVA was...
BioLineRx Ltd. (BLRX) - This analysis reviews how the stock price reacted after the last 12...
CollPlant Biotechnologies Ltd. (CLGN) - This analysis reviews how the stock price reacted after the last...
Top Ships Inc. (TOPS) - This analysis reviews how the stock price reacted after the last...
from Goldman Sachs issued a price target of $20.00 for AEVA on 2026-08-24 00:20:28.The adjusted price target was set to $20.00.At the time of the announcement, AEVA was trading at...
Danielle Brill from Truist Financial issued a price target of $20.00 for SLDB on 2026-08-21 11:27:42.The adjusted price target was set to $20.00.At the time of the announcement, SLDB was...
from Credit Suisse issued a price target of $3.50 for CCIF on 2026-08-21 10:37:04.The adjusted price target was set to $3.50.At the time of the announcement, CCIF was trading at...
from Goldman Sachs issued a price target of $575.00 for PRAX on 2026-08-21 10:23:06.The adjusted price target was set to $575.00.At the time of the announcement, PRAX was trading at...
Harsh Kumar from BMO Capital issued a price target of $35.00 for QBTS on 2026-08-20 20:33:59.The adjusted price target was set to $35.00.At the time of the announcement, QBTS was...
In a landscape marked by rapid technological advancements, the company saw a revenue increase of $1.4 million for the three months ending September 30, 2024, fueled by new licenses and...
In a landscape of fluctuating revenues, the company celebrated a 25% revenue increase in Q3 2024, yet faced a 14% decline over nine months due to production challenges. Operating expenses...
In a landscape marked by financial challenges, the company faced fluctuating revenues, with a notable 25% increase in Q3 2024 overshadowed by a 14% decline over nine months. Operating losses...
In a tale of growth and ambition, the company witnessed its revenue soar from $6.0 million to $13.9 million, fueled by partnerships with Acadia Pharmaceuticals. However, operating expenses, particularly in...
In a transformative period, the company experienced a remarkable surge in revenue, driven by newly acquired oil and gas assets. Operating expenses showed notable trends, with a decrease in occupancy...
